Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gruber

Showing results (181-190 of 355) with videos related to

Pageof 36
Sort By:
Human Vaccines & Immunotherapeutics|November 27, 2014
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. An open-label trialMasanari Shiramoto, Shin Irie, Christine Juergens, et al.
The Pediatric Infectious Disease Journal|October 19, 2019
Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in ChinaFengcai Zhu, Yuemei Hu, Jingxin Li, et al.
The Pediatric Infectious Disease Journal|September 25, 2012
The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trialRosalyn Singleton, Jay Wenger, Joseph A Klejka, et al.
Geobiology|July 19, 2012
Spherical particles of halophilic archaea correlate with exposure to low water activity--implications for microbial survival in fluid inclusions of ancient haliteS Fendrihan, M Dornmayr-Pfaffenhuemer, F W Gerbl, et al.
Vaccine|September 6, 2021
Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 yearsJody Lawrence, Nicholas Kitchin, Annaliesa S Anderson, et al.
Vaccine|November 29, 2021
A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccinationKevin Cannon, Charles Elder, Mariano Young, et al.
Nature Communications|June 10, 2021
Structural basis for inhibition of the AAA-ATPase Drg1 by diazaborineMichael Prattes, Irina Grishkovskaya, Victor-Valentin Hodirnau, et al.
Clinical Hemorheology and Microcirculation|September 29, 2019
Growth-related micromorphological characteristics of the porcine femoral arteryA Nies, L Proft, M E Nehring, et al.
Nucleic Acids Research|December 11, 1999
MIPS: a database for genomes and protein sequencesH W Mewes, D Frishman, C Gruber, et al.
The Journal of Infectious Diseases|June 1, 1996
Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators GroupW C Gruber, R B Belshe, J C King, et al.
Pageof 36

Showing results (181-190 of 355) with videos related to

Sort By:
Pageof 36
Human Vaccines & Immunotherapeutics|November 27, 2014
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. An open-label trialMasanari Shiramoto, Shin Irie, Christine Juergens, et al.
The Pediatric Infectious Disease Journal|October 19, 2019
Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in ChinaFengcai Zhu, Yuemei Hu, Jingxin Li, et al.
The Pediatric Infectious Disease Journal|September 25, 2012
The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trialRosalyn Singleton, Jay Wenger, Joseph A Klejka, et al.
Geobiology|July 19, 2012
Spherical particles of halophilic archaea correlate with exposure to low water activity--implications for microbial survival in fluid inclusions of ancient haliteS Fendrihan, M Dornmayr-Pfaffenhuemer, F W Gerbl, et al.
Vaccine|September 6, 2021
Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 yearsJody Lawrence, Nicholas Kitchin, Annaliesa S Anderson, et al.
Vaccine|November 29, 2021
A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccinationKevin Cannon, Charles Elder, Mariano Young, et al.
Nature Communications|June 10, 2021
Structural basis for inhibition of the AAA-ATPase Drg1 by diazaborineMichael Prattes, Irina Grishkovskaya, Victor-Valentin Hodirnau, et al.
Clinical Hemorheology and Microcirculation|September 29, 2019
Growth-related micromorphological characteristics of the porcine femoral arteryA Nies, L Proft, M E Nehring, et al.
Nucleic Acids Research|December 11, 1999
MIPS: a database for genomes and protein sequencesH W Mewes, D Frishman, C Gruber, et al.
The Journal of Infectious Diseases|June 1, 1996
Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators GroupW C Gruber, R B Belshe, J C King, et al.
Pageof 36